CL2010001642A1 - Composicion farmaceutica topica en gel que comprende a) 0,25 a 4,5% de un agente activo para el tratamiento de la queratosis actinica, b) un agente queratoliticamente activo, c) un formador de gel, d) un solvente organico, y menos de 5% en peso de agua; util para el tratamiento de la queratosis actinica. - Google Patents
Composicion farmaceutica topica en gel que comprende a) 0,25 a 4,5% de un agente activo para el tratamiento de la queratosis actinica, b) un agente queratoliticamente activo, c) un formador de gel, d) un solvente organico, y menos de 5% en peso de agua; util para el tratamiento de la queratosis actinica.Info
- Publication number
- CL2010001642A1 CL2010001642A1 CL2010001642A CL2010001642A CL2010001642A1 CL 2010001642 A1 CL2010001642 A1 CL 2010001642A1 CL 2010001642 A CL2010001642 A CL 2010001642A CL 2010001642 A CL2010001642 A CL 2010001642A CL 2010001642 A1 CL2010001642 A1 CL 2010001642A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- active agent
- actinic keratosis
- organic solvent
- useful
- Prior art date
Links
- 208000009621 actinic keratosis Diseases 0.000 title abstract 4
- 239000013543 active substance Substances 0.000 title abstract 4
- 239000003960 organic solvent Substances 0.000 title abstract 2
- 239000000499 gel Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008252 pharmaceutical gel Substances 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica que comprende a) un agente activo para el tratamiento de la queratosis actínica, b) un agente queratoliticamente activo, c) un formador de geles, d) un solvente orgánico; y método para el tratamiento de la queratosis actínica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08012237A EP2143421A1 (en) | 2008-07-07 | 2008-07-07 | Topical composition for the treatment of actinic keratosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2010001642A1 true CL2010001642A1 (es) | 2011-04-08 |
Family
ID=40039993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2010001642A CL2010001642A1 (es) | 2008-07-07 | 2010-12-30 | Composicion farmaceutica topica en gel que comprende a) 0,25 a 4,5% de un agente activo para el tratamiento de la queratosis actinica, b) un agente queratoliticamente activo, c) un formador de gel, d) un solvente organico, y menos de 5% en peso de agua; util para el tratamiento de la queratosis actinica. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8569320B2 (es) |
| EP (2) | EP2143421A1 (es) |
| JP (2) | JP5654987B2 (es) |
| KR (1) | KR101689898B1 (es) |
| CN (2) | CN102088957A (es) |
| AR (1) | AR072685A1 (es) |
| AU (1) | AU2009267471B2 (es) |
| BR (1) | BRPI0915439B8 (es) |
| CA (1) | CA2729974A1 (es) |
| CL (1) | CL2010001642A1 (es) |
| CO (1) | CO6351710A2 (es) |
| CY (1) | CY1116111T1 (es) |
| DK (1) | DK2315581T3 (es) |
| EA (1) | EA019533B1 (es) |
| EC (1) | ECSP11010762A (es) |
| ES (1) | ES2532948T3 (es) |
| HR (1) | HRP20150222T1 (es) |
| IL (1) | IL210134A (es) |
| ME (1) | ME02147B (es) |
| MX (1) | MX2011000054A (es) |
| MY (1) | MY158428A (es) |
| NZ (1) | NZ590288A (es) |
| PE (1) | PE20110330A1 (es) |
| PL (1) | PL2315581T3 (es) |
| PT (1) | PT2315581E (es) |
| RS (1) | RS53887B1 (es) |
| SI (1) | SI2315581T1 (es) |
| TW (1) | TWI433692B (es) |
| UA (1) | UA101044C2 (es) |
| WO (1) | WO2010003568A1 (es) |
| ZA (1) | ZA201100653B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2552470C2 (ru) * | 2009-10-08 | 2015-06-10 | Эм Эс Ди Консьюмер Кэар, Инк. | Композиция с низким содержанием простого эфира и устройство для ее доставки |
| JP5950528B2 (ja) * | 2011-09-30 | 2016-07-13 | 小林製薬株式会社 | 皮膜形成性外用製剤 |
| US20140350120A1 (en) * | 2011-12-12 | 2014-11-27 | Leo Laboratories Limited | Topical composition comprising an ingenol derivative and an oily solvent |
| NZ606177A (en) * | 2012-01-30 | 2014-03-28 | Dolorgiet Gmbh & Co Kg | Compositions for the treatment of actinic keratosis |
| GB201222405D0 (en) * | 2012-12-12 | 2013-01-23 | Leo Lab Ltd | Gel compositions |
| WO2016016742A1 (en) * | 2014-07-31 | 2016-02-04 | Sun Pharmaceutical Industries Limited | Oral pharmaceutical composition of isotretinoin |
| WO2016038035A1 (en) | 2014-09-12 | 2016-03-17 | Antibiotx Aps | Antibacterial use of halogenated salicylanilides |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| PL3319637T3 (pl) * | 2015-07-10 | 2023-03-20 | Infectopharm Arzneimittel Und Consilium Gmbh | Zastosowanie wodorotlenku potasu w leczeniu rogowacenia słonecznego |
| GB201604484D0 (en) * | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| CA3055938A1 (en) | 2017-03-10 | 2018-09-13 | Athenex, Inc. | Methods of treating and/or preventing actinic keratosis |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| US20220175769A1 (en) * | 2020-12-08 | 2022-06-09 | Ankh Life Sciences Limited | Method of treatment of actinic keratoses |
| DK202370132A1 (en) * | 2023-03-14 | 2024-10-10 | Repoceuticals Aps | Compositions for use in the treatment of actinic keratosis |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US4234599A (en) * | 1978-10-04 | 1980-11-18 | Scott Eugene J Van | Treatment of skin keratoses with α-hydroxy acids and related compounds |
| US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| US5167649A (en) * | 1988-08-22 | 1992-12-01 | Zook Gerald P | Drug delivery system for the removal of dermal lesions |
| US5093360A (en) * | 1989-04-07 | 1992-03-03 | Yu Ruey J | Retinal, derivatives and their therapeutic use |
| GB9023701D0 (en) * | 1990-10-31 | 1990-12-12 | Efamol Holdings | Medical treatment |
| JP3117502B2 (ja) * | 1991-08-27 | 2000-12-18 | 株式会社資生堂 | 皮膚外用剤 |
| US5627187A (en) * | 1995-04-12 | 1997-05-06 | Katz; Bruce E. | 5-FU for treating actinic kerotoses |
| KR20000022054A (ko) * | 1996-06-20 | 2000-04-25 | 아타나스 라비다스 | 여드름의 국소 치료 제형 및 이의 제조방법 |
| US5993787A (en) * | 1996-09-13 | 1999-11-30 | Johnson & Johnson Consumer Products, Inc. | Composition base for topical therapeutic and cosmetic preparations |
| US5955097A (en) * | 1996-10-18 | 1999-09-21 | Virotex Corporation | Pharmaceutical preparation applicable to mucosal surfaces and body tissues |
| US6462071B1 (en) * | 2000-03-02 | 2002-10-08 | Vitreo-Retinal Technologies, Inc. | Agents for intravitreal administration to treat or prevent disorders of the eye |
| ES2223277B1 (es) * | 2003-06-19 | 2006-03-01 | Fernando Bouffard Fita | Composicion anestesica para administracion topica. |
| MXPA06002163A (es) * | 2003-08-25 | 2006-05-22 | Foamix Ltd | Espuma farmaceutica de penetracion. |
| US20050137164A1 (en) * | 2003-09-22 | 2005-06-23 | Moshe Arkin | Diclofenac compositions for the treatment of skin disorders |
| AU2005267396B2 (en) * | 2004-06-24 | 2009-09-17 | Idexx Laboratories, Inc. | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
| US20070053984A1 (en) | 2005-03-03 | 2007-03-08 | Monique Spann-Wade | Topical gels compositions |
| WO2006134406A1 (en) * | 2005-06-14 | 2006-12-21 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Stable pharmaceutical gel of diclofenac sodium |
| US7851431B2 (en) * | 2005-07-27 | 2010-12-14 | Prescription Dispensing Laboratories | Treatment of actinic keratoses with calcium channel blockers |
| US20070264317A1 (en) * | 2006-05-15 | 2007-11-15 | Perrigo Israel Pharmaceuticals Ltd. | Imiquimod cream formulation |
| WO2008047857A1 (fr) * | 2006-10-18 | 2008-04-24 | Fujifilm Corporation | Procédé de production d'une composition comprenant un composé difficilement soluble dans l'eau incorporé dans une matrice hydrophile et préparation pour une utilisation externe comprenant un agent ou médicament anticancéreux ayant un coefficient de partage octanol/eau (log p) de -3,0 ou plus mais pas plus de 3,0, incorporé |
-
2008
- 2008-07-07 EP EP08012237A patent/EP2143421A1/en not_active Withdrawn
-
2009
- 2009-06-29 ME MEP-2015-38A patent/ME02147B/me unknown
- 2009-06-29 MX MX2011000054A patent/MX2011000054A/es active IP Right Grant
- 2009-06-29 PE PE2010001215A patent/PE20110330A1/es not_active Application Discontinuation
- 2009-06-29 SI SI200931142T patent/SI2315581T1/sl unknown
- 2009-06-29 CN CN2009801266635A patent/CN102088957A/zh active Pending
- 2009-06-29 US US13/002,971 patent/US8569320B2/en active Active
- 2009-06-29 CA CA2729974A patent/CA2729974A1/en not_active Abandoned
- 2009-06-29 RS RS20150185A patent/RS53887B1/en unknown
- 2009-06-29 PT PT97768766T patent/PT2315581E/pt unknown
- 2009-06-29 HR HRP20150222TT patent/HRP20150222T1/hr unknown
- 2009-06-29 KR KR1020117002825A patent/KR101689898B1/ko active Active
- 2009-06-29 UA UAA201101405A patent/UA101044C2/ru unknown
- 2009-06-29 BR BRPI0915439A patent/BRPI0915439B8/pt active IP Right Grant
- 2009-06-29 MY MYPI2011000028A patent/MY158428A/en unknown
- 2009-06-29 CN CN201510185320.3A patent/CN104825384A/zh active Pending
- 2009-06-29 EP EP09776876.6A patent/EP2315581B1/en active Active
- 2009-06-29 WO PCT/EP2009/004682 patent/WO2010003568A1/en active Application Filing
- 2009-06-29 ES ES09776876.6T patent/ES2532948T3/es active Active
- 2009-06-29 PL PL09776876T patent/PL2315581T3/pl unknown
- 2009-06-29 AU AU2009267471A patent/AU2009267471B2/en active Active
- 2009-06-29 NZ NZ590288A patent/NZ590288A/xx unknown
- 2009-06-29 JP JP2011516999A patent/JP5654987B2/ja not_active Expired - Fee Related
- 2009-06-29 EA EA201100020A patent/EA019533B1/ru unknown
- 2009-06-29 DK DK09776876T patent/DK2315581T3/en active
- 2009-07-03 AR ARP090102493A patent/AR072685A1/es unknown
- 2009-07-06 TW TW098122756A patent/TWI433692B/zh active
-
2010
- 2010-12-20 IL IL210134A patent/IL210134A/en active IP Right Grant
- 2010-12-30 CL CL2010001642A patent/CL2010001642A1/es unknown
-
2011
- 2011-01-17 EC ECSP11010762 patent/ECSP11010762A/es unknown
- 2011-01-26 ZA ZA2011/00653A patent/ZA201100653B/en unknown
- 2011-02-07 CO CO11013458A patent/CO6351710A2/es not_active Application Discontinuation
-
2014
- 2014-10-16 JP JP2014211989A patent/JP2015038129A/ja not_active Withdrawn
-
2015
- 2015-03-13 CY CY20151100254T patent/CY1116111T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2010001642A1 (es) | Composicion farmaceutica topica en gel que comprende a) 0,25 a 4,5% de un agente activo para el tratamiento de la queratosis actinica, b) un agente queratoliticamente activo, c) un formador de gel, d) un solvente organico, y menos de 5% en peso de agua; util para el tratamiento de la queratosis actinica. | |
| BR112014000178A2 (pt) | composições tópicas | |
| BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
| SV2010003777A (es) | Compuestos organicos | |
| CL2009000393A1 (es) | Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular. | |
| NO20080068L (no) | Topisk unguale formuleringer | |
| BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
| CL2009000394A1 (es) | Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
| GT200900027A (es) | Compuestos organicos | |
| UY30759A1 (es) | Compuestos quimicos | |
| CR11441A (es) | Producto de dispersion solida que contiene un compuesto a base de n-aril urea | |
| CO6612278A2 (es) | Composición acuosa antitranspirante/desodorante | |
| BR112013018352A2 (pt) | composição de minociclina tópica e método | |
| CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
| BRPI0913326C1 (pt) | formulação farmacêuticas tópicas contendo uma baixa concentração de peróxido de benzoíla em suspensão aquosa e um solvente orgânico miscível em água | |
| BR112012020731A2 (pt) | pastilhas gelatinosas suaves com nicotina. | |
| CL2011001026A1 (es) | Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato. | |
| AR082155A1 (es) | Formulacion antiseptica y desinfectante que tiene contenido de yodo reducido | |
| RS53531B1 (en) | Brimonidine gel composition | |
| CL2007003643A1 (es) | Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas. | |
| CL2012003282A1 (es) | Composicion farmaceutica topica que comprende, en base al peso total de la composicion a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua y d) 25 a 70% en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atopica, entre otros. | |
| BR112015027436A8 (pt) | composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos | |
| BR112012027393A2 (pt) | composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| WO2013182998A4 (en) | Cosmetic and / or pharmaceutical composition for the treatment of skin inflammation and related syndromes |